Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYN NYSE:RCUS NASDAQ:TBPH NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$17.04-7.4%$18.28$8.06▼$25.00$2.82B1.091.36 million shs1.88 million shsRCUSArcus Biosciences$23.16-6.2%$23.84$7.91▼$28.72$2.92B0.85862,447 shs1.04 million shsTBPHTheravance Biopharma$16.29-0.5%$16.37$10.42▼$21.03$839.80M0.17378,989 shs242,786 shsTLXTelix Pharmaceuticals$9.30-2.5%$10.05$6.28▼$18.49$3.16B-0.1145,976 shs245,628 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics0.00%-11.85%-2.85%+14.67%+27.07%RCUSArcus Biosciences0.00%-8.56%-6.64%+4.68%+141.45%TBPHTheravance Biopharma0.00%+1.43%-4.29%+20.04%+47.96%TLXTelix Pharmaceuticals0.00%-1.38%-12.76%+23.67%-46.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$17.04-7.4%$18.28$8.06▼$25.00$2.82B1.091.36 million shs1.88 million shsRCUSArcus Biosciences$23.16-6.2%$23.84$7.91▼$28.72$2.92B0.85862,447 shs1.04 million shsTBPHTheravance Biopharma$16.29-0.5%$16.37$10.42▼$21.03$839.80M0.17378,989 shs242,786 shsTLXTelix Pharmaceuticals$9.30-2.5%$10.05$6.28▼$18.49$3.16B-0.1145,976 shs245,628 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics0.00%-11.85%-2.85%+14.67%+27.07%RCUSArcus Biosciences0.00%-8.56%-6.64%+4.68%+141.45%TBPHTheravance Biopharma0.00%+1.43%-4.29%+20.04%+47.96%TLXTelix Pharmaceuticals0.00%-1.38%-12.76%+23.67%-46.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYNDyne Therapeutics 2.94Moderate Buy$35.00105.40% UpsideRCUSArcus Biosciences 2.58Moderate Buy$35.1051.59% UpsideTBPHTheravance Biopharma 2.75Moderate Buy$21.8334.03% UpsideTLXTelix Pharmaceuticals 2.78Moderate Buy$21.13127.15% UpsideCurrent Analyst Ratings BreakdownLatest TBPH, TLX, DYN, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026RCUSArcus Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$46.005/27/2026TBPHTheravance Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/18/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00 ➝ $35.005/15/2026DYNDyne Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.005/13/2026DYNDyne Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$23.00 ➝ $24.005/11/2026RCUSArcus Biosciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$20.00 ➝ $22.005/8/2026TBPHTheravance Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/7/2026RCUSArcus Biosciences The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $34.005/4/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/20/2026DYNDyne Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026RCUSArcus Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYNDyne TherapeuticsN/AN/AN/AN/A$6.81 per shareN/ARCUSArcus Biosciences$247M11.79N/AN/A$5.84 per share3.96TBPHTheravance Biopharma$109.78M7.65N/AN/A$5.86 per share2.78TLXTelix Pharmaceuticals$803.79M3.93$0.04 per share220.57$1.23 per share7.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYNDyne Therapeutics-$446.21M-$3.22N/AN/AN/AN/A-58.28%-46.77%7/27/2026 (Estimated)RCUSArcus Biosciences-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)TBPHTheravance Biopharma$105.89M$2.207.4058.18N/A104.34%18.84%10.94%8/11/2026 (Estimated)TLXTelix Pharmaceuticals-$7.12MN/AN/A84.55N/AN/AN/AN/A8/20/2026 (Estimated)Latest TBPH, TLX, DYN, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026DYNDyne Therapeutics-$0.7723-$0.73+$0.0423-$0.73N/AN/A5/7/2026Q1 2026TBPHTheravance Biopharma$0.0280-$0.10-$0.1280-$0.10$17.78 million$17.70 million5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million3/31/2026Q4 2025TBPHTheravance BiopharmaN/A-$0.10N/A-$0.10N/A$17.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDYNDyne TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYNDyne Therapeutics0.1719.9219.92RCUSArcus Biosciences0.194.044.04TBPHTheravance BiopharmaN/A13.1413.14TLXTelix Pharmaceuticals1.081.431.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYNDyne Therapeutics96.68%RCUSArcus Biosciences92.89%TBPHTheravance Biopharma99.10%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipDYNDyne Therapeutics9.46%RCUSArcus Biosciences9.60%TBPHTheravance Biopharma7.65%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYNDyne Therapeutics100165.31 million149.68 millionOptionableRCUSArcus Biosciences500125.77 million113.70 millionOptionableTBPHTheravance Biopharma11051.55 million47.61 millionOptionableTLXTelix Pharmaceuticals1,184339.38 millionN/AN/ATBPH, TLX, DYN, and RCUS HeadlinesRecent News About These CompaniesTelix Pharmaceuticals Limited (TLX) Presents at 46th Annual William Blair Growth Stock Conference - SlideshowJune 3, 2026 | seekingalpha.comTelix and United Imaging Announce Strategic Theranostics CollaborationJune 2, 2026 | globenewswire.comProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026June 1, 2026 | globenewswire.comIs Telix (ASX:TLX) Quietly Assembling a Connected Oncology Platform That Reshapes Its Moat?May 29, 2026 | finance.yahoo.comTelix to Participate in William Blair Growth Stock and Jefferies Global Healthcare ConferencesMay 27, 2026 | globenewswire.comTelix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving UpMay 18, 2026 | seekingalpha.comIPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms DosingMay 18, 2026 | globenewswire.comTelix Pharmaceuticals Ltd ADR TLXMay 17, 2026 | morningstar.comMTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesMay 15, 2026 | globenewswire.comTelix Issues New Shares to Complete Deferred ImaginAb Acquisition PaymentMay 10, 2026 | theglobeandmail.comMauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic SurgeryMay 8, 2026 | businesswire.comChristian Behrenbruch Acquires 33,435 Shares of Telix Pharmaceuticals (NASDAQ:TLX) StockMay 7, 2026 | insidertrades.comNew Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCCMay 4, 2026 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 - SlideshowMay 2, 2026 | seekingalpha.comInsider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of SharesMay 1, 2026 | finance.yahoo.comTLX101-Px (Pixlumi®) MAA Accepted in EuropeApril 30, 2026 | globenewswire.comHow TLX597-Tx Phase 2 Dosimetry Data Will Impact Telix Pharmaceuticals (ASX:TLX) InvestorsApril 30, 2026 | finance.yahoo.comTelix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 TranscriptApril 30, 2026 | seekingalpha.comOPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate CancerApril 29, 2026 | globenewswire.comEducational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio ApproachApril 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent StocksBy Leo Miller | May 18, 2026TBPH, TLX, DYN, and RCUS Company DescriptionsDyne Therapeutics NASDAQ:DYN$17.04 -1.37 (-7.44%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$17.80 +0.76 (+4.43%) As of 06/5/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Arcus Biosciences NYSE:RCUS$23.16 -1.54 (-6.22%) Closing price 06/5/2026 03:59 PM EasternExtended Trading$23.14 -0.02 (-0.08%) As of 06/5/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Theravance Biopharma NASDAQ:TBPH$16.29 -0.08 (-0.49%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$16.28 0.00 (-0.03%) As of 06/5/2026 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Telix Pharmaceuticals NASDAQ:TLX$9.30 -0.24 (-2.52%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$9.30 -0.01 (-0.05%) As of 06/5/2026 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Petco Faces Tough Competition, But Momentum Is Building IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
